Related Experiment Video
Updated: Jul 2, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
Kurt Van Baelen1, Veerle Van Eygen, Evelien Rondelez
1Virco BVBA, Generaal De Wittelaan L11 B4, 2800Mechelen, Belgium. kvbaele1@vrcbe.jnj.com
Abstract:
The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Size and Structure of Viral Genomes
Retroviruses
Non-LTR Retrotransposons

